Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
NSCLC
Interventions
DRUG

Icotinib of routine dose

Icotinib of routine dose: 125 mg is administered orally three times per day.

DRUG

Icotinib of high dose

Icotinib: 250 mg is administered orally three times per day.

Trial Locations (17)

310000

RECRUITING

Sir Run Run Shaw Hospital, Hangzhou

RECRUITING

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

310006

ACTIVE_NOT_RECRUITING

Zhejiang Traditional Chinese Medical Hospital, Hangzhou

310007

ACTIVE_NOT_RECRUITING

Zhejiang Hospital, Hangzhou

310014

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

315040

RECRUITING

Yinzhou People's Hospital, Ningbo

315046

RECRUITING

Ningbo Medical Treatment Center Lihuili Hospital, Ningbo

317000

RECRUITING

Taizhou Hospital of Zhejiang Province, Taizhou

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical College, Wenzhou

350000

RECRUITING

Fujian Hospital for Chest Tumors & Tuberculosis Diseases, Fuzhou

350001

RECRUITING

Fujian Provincal Hospital, Fuzhou

350014

RECRUITING

Fujian Provincal Cancer Hospital, Fuzhou

361024

RECRUITING

The second hospital of Xiamen City, Xiamen

410006

RECRUITING

Hunan Provincal Cancer Hospital, Changsha

610041

RECRUITING

The Second People's Hospital of Sichuan, Chengdu

All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease | Biotech Hunter | Biotech Hunter